16-Hydroxyicosa-5,8,11,14-tetraenoic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 16-Hydroxyicosa-5,8,11,14-tetraenoic acid
• 化学式: C₂₀H₃₂O₃
• 分子量: 320.5
• InChiKey: JEKNPVYFNMZRJG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  23
• 可旋转键数：
  14
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  16-Hydroxyicosa-5,8,11,14-tetraenoic acid 、 16R‑HETE 、 20-羟基二十碳-5Z,8Z,11Z,14Z-四烯酸 在 solution M199 、 乙二胺四乙酸 、 M199 作用下， 反应 0.67h， 生成 16-HETE
  参考文献：
  名称：

  Methods and products related to 16-HETE analogs

  摘要：

  本发明包括16-HETE类似物，它们是16-HETE的激动剂和拮抗剂。这些组合物可以制成药学上可接受的配方。本发明还包括使用16-HETE激动剂抑制中性粒细胞黏附和中性粒细胞聚集的方法和产品。本发明的一种方法涉及将16-HETE激动剂与溶栓剂联合给患有血栓栓塞性卒中的患者进行治疗。

  公开号：

  US06359158B1

文献信息

• Arachidonic acid metabolite, 16-hete
  申请人：University of Vermont

  公开号：US05753702A1

  公开（公告）日：1998-05-19

  The present invention provides methods and products for inhibiting neutrophil adhesion and neutrophil aggregation. The invention includes a method for treating a subject to inhibit neutrophil adhesion and neutrophil aggregation by administering 16-hydroxyeicosatetraenoic acid (16-HETE) to the subject. 16-HETE is an arachidonic acid metabolite. The invention also includes a pharmaceutical preparation of 16-HETE.

  本发明提供了一种抑制中性粒细胞粘附和聚集的方法和产品。该发明包括一种通过向受试者注射16-羟基二十四碳六烯酸（16-HETE）来抑制中性粒细胞粘附和聚集的治疗方法。16-HETE是一种花生四烯酸代谢产物。该发明还包括16-HETE的制药制剂。
• Methods and products relating to 16-HETE analogs
  申请人：University of Vermont and State Agricultural College

  公开号：US20020165262A1

  公开（公告）日：2002-11-07

  The present invention includes 16-HETE analogs which are agonists and antagonists of 16-HETE. The compositions may be formulated in pharmaceutically acceptable formulations. The invention also includes methods and products for inhibiting neutrophil adhesion and neutrophil aggregation using the 16-HETE agonists. One method of the invention involves the administration of a 16-HETE agonist in combination with a thrombolytic agent to a patient suffering from thromboembolic stroke.

  本发明涉及16-HETE类似物，其是16-HETE的激动剂和拮抗剂。这些组合物可以制成药学上可接受的制剂。本发明还包括使用16-HETE激动剂抑制中性粒细胞粘附和中性粒细胞聚集的方法和产品。本发明的一种方法涉及将16-HETE激动剂与溶栓剂联合给患有血栓栓塞性中风的患者治疗。
• Arachidonic acid metabolite, 16-HETE
  申请人：The University of Vermont and State Agricultural College

  公开号：US06140364A1

  公开（公告）日：2000-10-31

  The present invention provides methods and products for inhibiting neutrophil adhesion and neutrophil aggregation. The invention includes a method for treating a subject to inhibit neutrophil adhesion and neutrophil aggregation by administering 16-hydroxyeicosatetraenoic acid (16-HETE) to the subject. 16-HETE is an arachidonic acid metabolite. The invention also includes a pharmaceutical preparation of 16-HETE. Methods and products are also provided for treating thromboembolic stroke. The method involves the administration of 16-HETE in combination with a thrombolytic agent to a patient suffering from thromboembolic stroke. Preferably, the 16-HETE is 16(R)-HETE and the thrombolytic agent is tPA. The product is a pharmaceutical preparation of 16-HETE and a thrombolytic agent and a pharmaceutically acceptable carrier.

  本发明提供了抑制中性粒细胞粘附和聚集的方法和产品。该发明包括通过向受试者投予16-羟基二十四碳六烯酸（16-HETE）来治疗受试者以抑制中性粒细胞粘附和聚集的方法。16-HETE是花生四烯酸代谢产物。本发明还包括16-HETE的药物制剂。还提供了治疗血栓栓塞性中风的方法和产品。该方法涉及向患有血栓栓塞性中风的患者投予16-HETE和溶栓剂的组合物。优选地，16-HETE是16（R）-HETE，而溶栓剂是tPA。该产品是16-HETE和溶栓剂以及药学上可接受的载体的药物制剂。
• Methods and products related to 16-HETE analogs
  申请人：University of Vermont and State Agricultural College

  公开号：US20030176509A1

  公开（公告）日：2003-09-18

  The present invention includes 16-HETE analogs which are agonists and antagonists of 16-HETE. The compositions may be formulated in pharmaceutically acceptable formulations. The invention also includes methods and products for inhibiting neutrophil adhesion and neutrophil aggregation using the 16-HETE agonists. One method of the invention involves the administration of a 16-HETE agonist in combination with a thrombolytic agent to a patient suffering from, thromboembolic stroke.

  本发明包括16-HETE类似物，它们是16-HETE的激动剂和拮抗剂。这些组合物可以制成药用制剂。本发明还包括使用16-HETE激动剂抑制中性粒细胞粘附和中性粒细胞聚集的方法和产品。本发明的一种方法涉及将16-HETE激动剂与溶栓剂联合给患有血栓性卒中的患者进行治疗。